Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 6/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598432 | 0.87 | NPC1 (0.41) | NPC1LMNASMYD3BRD4TTK | |
| SCHEMBL25273870 | 0.84 | NPC1 (0.41) | NPC1LMNASMYD3BRD4TTK | |
| SCHEMBL25273869 | 0.84 | NPC1 (0.41) | NPC1LMNASMYD3BRD4TTK | |
| SCHEMBL29316717 | 0.81 | NPC1 (0.44) | NPC1LMNASMYD3BRD4PTGES | |
| SCHEMBL25604714 | 0.81 | DRD3 (0.42) | PDE4APDE4BPDE4CPDE4DCRHR1 | |
| SCHEMBL25604202 | 0.80 | NPC1 (0.42) | NPC1LMNARAB9A | |
| SCHEMBL25605757 | 0.80 | AHR (0.44) | NPC1RAB9A | |
| SCHEMBL25606054 | 0.80 | ATR (0.40) | BRD4CD38 | |
| SCHEMBL25604839 | 0.80 | KDM4E (0.36) | NPC1TTKPDE4APDE4BPDE4C | |
| SCHEMBL25604083 | 0.80 | ADRA1D (0.38) | NPC1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303567-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11667636-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667636-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 2003/4885LMNA 3604/4885SMYD3 3288/4885 |
| US-20230303567-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | NPC1 2003/4885LMNA 3604/4885SMYD3 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.